烯-胺混合物作为具有选择性抗癌活性的强效阿尔多缩酶抑制剂:理性设计,合成和分子洞察力
Saliha Gundogdu1, Hatice Esra Duran2, Mustafa Arslan3
1Department of Chemistry, Faculty of Sciences, Sakarya University, Sakarya, 54187, Türkiye.
Bioorganic chemistry
|June 26, 2025
概括
研究人员设计了针对癌症中的阿尔多缩小酶 (ALR2) 的新型氨基-胺混合体. 化合物5a表现出强大的ALR2抑制和选择性抗癌活性,为精密瘤治疗提供了新的线索.
科学领域:
- 生物化学和分子生物学
- 药用化学 医学化学
- 癌症研究 癌症研究
背景情况:
- 癌细胞中的代谢重编程对精确瘤学具有脆弱性.
- 阿尔多斯减少酶 (ALR2,AKR1B1) 与瘤进展和耐药性有关,但仍然是一个未被充分利用的癌症标.
- 向ALR2为新型抗癌疗法提供了潜在的战略.
研究的目的:
- 设计,合成和评估新型烯-甲胺-碳素酸混合物作为具有选择性抗癌潜力的双重作用剂.
- 确定用于癌症治疗的阿尔多缩酶 (ALR2) 强抑制剂.
- 探索这些新型化合物的结构-活性关系和类似药物的特性.
主要方法:
- 烯-甲胺碳酸-碳酸混合物 (化合物5a-5l) 的合理设计和合成.
- 在体外生物评估包括ALR2抑制试验和癌细胞系中的抗增殖活性.
- 分子对接,MM-GBSA计算,随机森林回归建模,SHAP分析,以及在中ADME/Tox分析.
主要成果:
- 化合物5a表现出强大的ALR2抑制 (KI = 8.71 nM),明显超过临床比较剂epalrestat.
- 化合物5a表现出针对MCF-7和A549癌细胞的选择性抗增殖活性,节省了正常细胞.
- 分子建模证实了5a与ALR2的高亲和结合,QSAR/SHAP分析确定了影响功效的关键物理化学描述因素.
结论:
- 化合物5a代表了第一类,机械验证的ALR2向抗癌,具有新型化学型.
- 这些发现支持5a的开发,用于代谢向的精确疗法.
- 这项研究证实ALR2是开发新型抗癌药物的有希望的目标.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
10:42Preparation of N-2-alkoxyvinylsulfonamides from N-tosyl-1,2,3-triazoles and Subsequent Conversion to Substituted Phthalans and Phenethylamines
Published on: January 3, 2018
9.9K
相关概念视频
Phase I Reactions: Reductive Reactions
273
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
273
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
